The tale of two organs: allogeneic hematopoietic stem cell transplantation following liver transplantation in a myelofibrosis patient

Le résumé fourni par la source

T a g g e d H 1 IntroductionT a g g e d E n d T a g g e d P MF is a myeloproliferative neoplasm (MPN) in which proinflammatory cytokines derived from malignant cells drive bone marrow fibrosis typical of the disease.Patients with this condition can progress to bone marrow failure, with extramedullary hematopoiesis in the liver and spleen. 1 Indeed, MPNs represent one of the most common underlying reasons for patients requiring liver transplantation. 2 Definitive treatment of MF requires allogenic hematopoietic T a g g e d E n d T a g g e d P stem cell transplant (alloHSCT), which has been shown to provide an overall survival benefit in patients with disease classified as Intermediate-1 or greater by the Dynamic International Prognostic Scoring System (DIPSS).However, risks of alloHSCT may outweigh potential benefits in patients with less severe disease.3 Due to a paucity of literature, it is currently unclear how prior liver transplantation impacts this risk stratification.Clinicians seeking to practice evidence-based care would benefit from further descriptions of outcomes following sequential transplantations.To this end, we provide a description of our T a g g e d E n d MF, Myelofibrosis; MPN, Myeloproliferative Neoplasm; alloHSCT, Allogeneic Hematopoeitic Stem Cell Transplant; DIPSS, Dynamic International Prognostic Scoring System;

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.